

## Index

- absolute reaction rate theory, 134–7, 264  
 applied to gating, 181  
 acetylcholine, 68  
 binding site, in nAChR, 79, 175, 176fig.  
 inhibition of heart by, 101, 205  
 membrane noise produced by, 40fig., 41, 174  
 acetylcholine receptor  
 muscarinic, 69, 215–17  
 nicotinic, *see* nAChR  
 aconitine, 240  
 action potential  
 of heart muscle, 93, 203, 213  
 of nerve axon, 4, 28, 89, 195  
 of skeletal muscle, 34  
 activation, 195, 198fig.; *see also* gating  
 activity of ions, 19  
 activity coefficient, 19  
 adenyl cyclase, 212, 216  
 aerolysin, 118  
 affinity, 170, 226  
 $\omega$ -agatoxins, 93, 244  
 agonists, 244  
 AKT1, 99  
 alamethicin, 116–18  
 allosteric effects  
 of blocking agents, 243–4  
 in cyclic-nucleotide-gated channels, 200–1  
 in gating, 161  
 in modulation, 212, 246  
 in nAChR, 173, 177  
 amiloride, 102  
 amino acid residues, properties of, 62tab., 72  
 amino acid sequences  
 determination of, 59–68  
 evolution of, 64  
 of glutamate receptors, 87fig.  
 of nAChR, 70, 71 fig., 86fig.  
 of voltage-gated sodium channel, 91  
 $\gamma$ -aminobutyric acid receptor *see* GABA receptor  
 4-aminopyridine (4-AP), 234  
 AMPA, 86, 247  
 AMPA receptors, 86  
 pharmacology of, 247–8  
 anaesthetics  
 general, 246, 248  
 local, 240–2  
 anatoxin A, 245  
 ångström unit (Å), 18  
 anomalous mole-fraction effect, 132–3, 140, 141  
 antagonists, 244  
 antechamber, of channel pore, 231; *see also* vestibule  
 apamin, 234  
 APV, 248  
 aquaporins, 113  
 arachidonic acid, 221  
 assembly of *Shaker* channels, 97  
 association constant, 170  
 asthma, 234, 258  
 atmosphere, ion, 20  
 ATP (adenosine triphosphate) as gating agent  
 in ATP-sensitive potassium channels, 3, 205  
 in CFTR channel, 206–7  
 ATP as source of cAMP, 212, 216  
 ATP receptor channel, 89  
 ATP-binding cassette (ABC) superfamily, 109  
 ATP-sensitive potassium channels *see* potassium channels, ATP-sensitive  
 auxilliary subunits, 93, 192–3, 213  
 bacteriorhodopsin, 73  
 ball and chain model, 189–91, 230  
 barbiturates, 246  
 batrachotoxin, 183fig., 239  
 Bay K 8644, 244  
 Becker's disease *see* myotonia, generalized  
 benzodiazepines, 246–7  
 $\beta$ -barrel, 74, 78, 114, 115fig., 153  
 $\beta$  cell, 3, 234  
 $\beta$ -sheet, 73, 115  
 bicuculline, 246  
 bilayer, lipid, 2fig.  
 artificial, 5, 43–5  
 binding site models of channels, 134–44  
 BIR channels, 101, 102tab., 204  
 BK channels, 97, 98

- block, kinetics of, 226–9  
 Boltzmann constant ( $k$ ), 11tab., 24  
 Boltzmann distribution, 181  
 Boltzmann relation, 182, 183fig.  
 brevetoxins, 240  
 bright ideas, value of, 263  
 $\alpha$ -bungarotoxin, 69, 245  
 bursts, 166, 227
- C terminus, 63, 75  
 $C_9$ , block by, 229–30  
 calcium channels, voltage-gated  
   binding site model of, 142–4  
   blocking agents of, 243–4  
   dysfunctional mutants of, 254–5  
   inactivation, 220  
   modes of, 219, 243–4  
   molecular basis of selectivity in,  
     154–6  
   phosphorylation of, 213–14  
   S4 segment of, 186fig.  
   selectivity of, 127tab., 142  
   structure and diversity of, 93–4  
 calcium ions  
   as gating agents, 201–2  
   as intracellular messengers, 25, 93,  
     103–5, 213, 220, 221  
   as modulators, 219–20  
   and surface charges, 222–3  
 calcium release channels, 103–6, 261  
 calmodulin, 211, 220, 221  
 cAMP (cyclic adenosine  
   monophosphate), 99, 199, 215–16  
 cAMP-dependent protein kinase *see*  
   protein kinase A  
 cAMP-gated channel, olfactory, 99, 199  
 capacitance, 12  
 capacity current, 37, 38fig., 180  
 capsaicin, 236  
 carbachol, 245  
 cDNA, 66  
 cell-attached patch configuration, 48  
 cell lines, expression in, 81  
 CFTR (cystic fibrosis conductance  
   regulator) channel  
   functions of, 257  
   gating of, 206–7  
   identification of, 67, 108  
   mutations affecting, 257–60  
   structure of, 108–9  
 cGMP (cyclic guanosine  
   monophosphate), 98, 199, 222  
 cGMP-gated channel, photoreceptor,  
   98, 199  
   selectivity of, 127  
 chaos, in gating model, 168  
 Charcot–Marie–Tooth disease, 261  
 charge, electric, 9, 10tab.  
 charge immobilization, 180, 193–4  
 charybdotoxin, 98, 234–6  
 chemical bonds, 13–17  
 chemically gated channels *see* ligand-  
   gated channels  
 CHIP28, 113  
 chloride channels  
   background, 106–9  
   dysfunctional mutants of, 256–60  
   neuronal, 128  
   neurotransmitter-gated *see* GABA  
     receptor *and* glycine receptor  
 chlorpromazine, 77, 245  
 chord conductance, 30  
 ciguatoxin, 240  
 CIR subunit, 101, 102tab.  
 CLC (ClC) channels, 106–8  
   dysfunctional mutants of, 256–7  
 closed times, distribution of, 55–7,  
   163–6  
 clusters, 166  
 CMTX, 261  
 CNG channel *see* cyclic-nucleotide-  
   gated channels  
 codon, 62  
 colicins, 118  
 conantokins, 248  
 concentration cell, 24  
 conductance, 10tab., 12  
 conductive state, 162  
 conductivity, 12  
 conformational state, 162  
 connexins, 110–12, 210, 261  
 connexons, 110, 210  
 conotoxins, 238–9, 244, 245, 248  
   conantokins, 248  
    $\alpha$ -conotoxins, 245  
    $\mu$ -conotoxins, 239  
    $\omega$ -conotoxins, 94, 244  
 constant field model, 122–4, 223fig.  
 covalent bond, 13, 17tab.  
 CPP, 248  
 cromakalim, 234  
 cryoelectron microscopy *see* image  
   analysis, quantitative  
 crystal radius of ions, 17–19  
 curare, 245  
 current, electric, 10tab., 11  
 currents, single-channel, 6fig., 28–31  
   amplitudes of, 53  
   analysis of, 52–7  
   time characteristics of, 55–7  
 curare, 176fig.  
 cyclic nucleotides *see* cAMP *and* cGMP  
 cyclic-nucleotide-gated channels  
   binding sites of, 200  
   gating in, 199–201  
   molecular basis of selectivity in,  
     156–7  
   structure of, 98–9  
 cysteine substitution method, 153–4  
 cystic fibrosis, 108, 257–60 *see also* CFTR  
 cytoskeleton, 209  
 cytotoxicity, 251
- dantrolene, 261  
 Debye length, 20, 222  
 dendrotoxin, 192, 234, 245tab.  
 dephosphorylation, 211  
 desensitization, in nAChR, 173, 245  
 diabetes, treatment of, 3, 234  
 diacylglycerol, 105, 211, 213  
 diazepam, 246  
 diffusion, 21–2  
 diffusion models of gating, 167–8  
 dihydropyridine receptor, 103  
 dihydropyridines, 243  
 diltiazem, 243  
 diphtheria toxin, 118  
 dipole, electric, 12  
 dipole–dipole interaction, 15  
 disease, channel dysfunction in, 251–62  
 disulphide bridges, 72  
   in nAChR, 75  
 DNA  
   complementary DNA (cDNA), 66  
   non-coding, 64  
   recombinant, 64–8  
   structure of, 60–1, 68

- DNA library, 66  
 domoic acid, 247  
 dose–response curve, 168–9  
 DRK1 (Kv2.1), 96tab., 153  
 dwell time, 55  
 dwell time histogram, 56, 164, 229fig.
- eag* (*ether-à-go-go*), 99, 255  
 EC<sub>50</sub> and ED<sub>50</sub>, 169  
 electric charge, 9, 10tab.  
 electric organs of fish, 69, 91  
 electrical distance,  $\kappa\delta$ , 138, 183, 201, 231–3  
 electricity, 9–13  
 electrochemical gradient, 23–6  
   in cells, 26–7  
   defined 1, 23  
 electrodiffusion, 21, 23, 121–9  
 elementary charge ( $e_0$ ), 10, 11tab., 24  
 end-plate potential, 34, 35fig.  
 energy barrier, 121, 134  
 energy profile, 134, 135fig., 139fig., 141fig., 143fig.  
 episodic ataxia with myokymia syndrome, 255  
 epitope protection assay, 76  
 equilibrium potential, 24, 124–5  
 exons, 63, 82, 95  
 expression of channel proteins, 79–81
- Faraday constant ( $F$ ), 10, 11tab.  
 fatty acids, 209, 220–1  
 feet, in muscle, 103  
 first latency, 167  
 flickering, 174  
 flickery block, 226  
 flip/flop segment, 88, 89fig.  
 fluctuation analysis, 39–43  
 fluxes, ionic, 123, 131, 136  
 foot in the door model, 196  
 fractal models of gating, 167–8
- G proteins, 101, 105, 204  
 modulation by, 214–19
- GABA receptor channel  
 anomalous mole-fraction effect in, 133, 140  
 binding site model of, 140
- molecular basis of selectivity in, 159–60  
 pharmacology of, 246–7  
 selectivity of, 128  
 structure of, 84–5
- gap junction channels  
 dysfunctional mutants of, 261  
 gating of, 209–10  
 modulation by calcium ions, 220  
 pore size, 147–8  
 selectivity of, 128–9  
 structure of, 110–12
- gas constant ( $R$ ), 11tab., 24
- gating, 2, 7fig., 161  
 kinetics of, 161–70, 194–9  
 of nAChR channel, 170–8  
 of voltage-gated channels, 178–99
- gating charges, 179–84  
 gating currents, 179–80, 195–7
- gene, 63  
 CFTR, 258–9  
 duplication, 83  
 dysfunctional, 251–62  
 of mammalian potassium channels, 64  
 of nAChR, 82  
 of *Shaker* channel, 63
- gene therapy, in cystic fibrosis, 260
- genetic code, 62, 63tab.
- gigaseal, 48
- GHK (Goldman–Hodgkin–Katz) equations, 123–4
- GIRK1 channel, 101, 204, 218
- glibenclamide, 234
- glutamate receptor channels, 85–8  
 calcium permeability of, 160  
 molecular basis of selectivity in, 160  
 pharmacology of, 247–9  
*see also* NMDA receptor channels
- glycine, as modulator, 219
- glycine receptor channel  
 block of, 247  
 dysfunctional mutants of, 260  
 molecular basis of selectivity in, 159–60  
 structure of, 84–5
- glycosylation site, 72  
 in nAChR, 75  
 in voltage-gated sodium channel, 92
- gramicidin channel  
 currents through, 5, 46fig.  
 molecular dynamics in, 122, 148–9  
 streaming potential in, 151  
 structure of, 115–16  
 water movement through, 148
- grayanotoxins, 240
- H5 segment, 90  
 consensus sequence in, 154  
 C-type inactivation and, 191  
 of inward rectifier channels, 100, 152  
 of voltage-gated potassium channels, 152–4
- hair cells, 209
- halothane, 246, 261
- headstage, 50  
 $\alpha$ -helix, 72, 73fig.
- hereditary hyperekplexia, 260
- HERG, 255–6
- heteromultimers in potassium channels, 97
- heterotrimeric G protein *see* G protein
- hexamers, gap junction, 110
- Hill coefficient, 170, 206
- Hill–Langmuir equation, 169
- hinged lid model, 192–3, 212, 253
- histronicotoxin, 245
- Hodgkin–Huxley equations, 4, 38, 195
- homology, of sequences, 64, 81
- HOPP, 254
- 5-HT (5-hydroxytryptamine, serotonin) *see next entry*
- 5-HT-gated channel, 85
- hydration, of ions, 20–1, 136
- hydrogen bond, 15, 17tab.  
 in channel pore, 146, 148  
 in proteins, 72, 74
- hydrogen ions  
 block by, 137–8, 227  
 local anaesthetics affected by, 242  
 surface charges and, 222–3
- hydropathy index, 62tab., 74
- hydropathy profile, 74  
 of nAChR, 74fig.  
 of voltage-gated sodium channel, 91fig.
- hydrophobic bond, 16, 17tab.

- hydrophobicity profile *see* hydrophathy profile
- 5-hydroxytryptamine *see* 5-HT
- hyperkalaemic periodic paralysis (HYPP), 251–3, 255fig.
- hypokalaemic periodic paralysis (HOPP), 254–5, 256fig.
- $I_{\text{Cn}}$  protein, 114
- ibotenic acid, 248
- image analysis, quantitative, 77, 110, 177, 210
- inactivation, 188–94  
 ball and chain model, 189–91  
 C-type, 191–2  
 hinged-lid model of, 192–3, 212  
 kinetics of, 164, 196–7  
 local anaesthetics and, 242  
 mutations affecting, 253, 254–5, 255fig.  
 phosphorylation and, 212
- influenza virus, 118
- inositol trisphosphate receptor *see*  $\text{IP}_3$  receptor
- inside-out patch configuration, 48
- $\text{InsP}_3$  *see*  $\text{IP}_3$
- introns, 63, 82
- ion channels  
 in  $\beta$  cells, 3  
 different types of, 7–8  
 discovery of, 3–6  
 in muscle cells, 34, 37  
 nature of, 1  
 in nerve axons, 28, 37  
 papers on, 263
- ion pairs, in *Shaker* channel, 187
- ion–dipole interaction, 15, 136
- ionic bond, 14, 17tab.
- ionic concentrations in cells, 26
- ionotropic receptors, defined, 84
- ions  
 block by, 133–4, 248  
 in crystals, 17–19  
 hydration of, 20–1  
 nature of, 14  
 rates of movement, 23  
 size of, 17–19, 21  
 in solution, 19–23
- $\text{IP}_3$  (inositol 1,4,5-trisphosphate) receptor, 104–6, 219
- IRK1 channel, 100, 102tab., 203
- IsK protein, 113
- interdependence of ion movements, 129–34
- jump experiments, 166–7
- kainate receptors, 86, 247
- kainic acid, 247
- KAT1, 99
- $\text{K}_{\text{ATP}}$  channels *see* potassium channels, ATP-sensitive
- $\text{K}(\text{Ca})$  channels *see* potassium channels, calcium-activated
- kinetics of gating, 161–8  
 in cyclic-nucleotide-gated channels, 200–1  
 in nAChR, 171–4  
 in voltage-gated channels, 194–9
- Kir subfamily, 101, 102tab.
- Kv channel nomenclature, 96
- leucine heptad, 188
- library, recombinant DNA, 66
- lidocaine, 240
- ligand-gated channels, 7fig., 8  
 kinetics of, 168–70
- lipid bilayer, artificial, 5, 43–5
- liposomes, 45, 260
- long QT syndrome, 256
- long-pore effect, 131–2
- lophotoxin, 245
- M current, 216–17
- $\text{M}_2$  protein, influenza virus, 118
- M2 segment  
 of GABA and glycine receptors, 159  
 of glutamate receptors, 88, 160, 248  
 of inward rectifier potassium channels, 204fig.  
 of nAChR, 77, 78, 157–9
- magnesium ions, block by, 203, 205fig.
- margainin, 118
- Markov process, 162
- maxi-K channels, 97, 98
- MDR1, 109
- mechanosensitive channels, 207–9
- mellitin, 118
- membrane, plasma, 1
- membrane-crossing segments *see* transmembrane segments
- messenger RNA (mRNA), 62
- metabotropic receptors, 84
- Michaelis constant,  $K_m$ , 130
- Michaelis–Menten relation, 130
- microelectrodes, intracellular, 33–5
- minK protein, 113–14
- MIP, 112
- mitochondrial VDAC, 115
- modes, 219, 243–4
- modulation, 161, 210–23
- molecular biological techniques, 59–68, 60tab.
- molecular dynamics, 122, 149fig.
- mouth, of channel pore, 152, 154, 189fig., 230, 231, 234, 237
- mRNA, 62
- multiple drug resistance (MDR) protein, 109
- multi-state channel, kinetics of, 164–6
- mutagenesis, site-directed, 68, 69fig.
- mutations, 68
- myasthenia gravis, 251
- myokymia, 255
- myotonia, generalized, 256–7; *see also* potassium-aggravated myotonia
- myotonia congenita, 107–8, 187, 256–7
- N terminus, 63, 75
- nAChR (nicotinic acetylcholine receptor) channel  
 acetylcholine binding site, 175, 176fig.  
 allosteric nature of, 173, 177  
 amino acid sequence of, 70, 71fig.  
 block by acetylcholine, 173–4  
 blocking agents of, 245  
 conformational change in, 172–3, 178  
 desensitization of, 173  
 evolution of, 81–4  
 foetal subunit, 177  
 gating of, 170–8  
 ion binding site model of, 140  
 kinetics of gating, 171–4

- molecular basis of selectivity, 157–9  
 neuronal, 82, 158  
 phosphorylation of, 214  
 pore size, 147, 148fig., 151–2  
 streaming potential in, 151–2  
 structure of, 68–79, 175–9  
 subconductance states of, 174  
 subunits of, 69, 77, 81–4, 176–7, 178fig.  
 transition time of, 167  
 nAChR-related receptor family, 84, 86fig.  
 neosurugatoxin, 245  
 nereistoxin, 245  
 Nernst equation, 24, 124  
 Nernst potential, 24, 26tab., 27  
 neurotransmitter-gated channels, 7, 84–9  
 pharmacology of, 244–9  
 neurotransmitters, modulation by, 214–19  
 NGK2 (Kv3.1), 96tab., 153  
 nicorandil, 234  
 nicotine, 245  
 nicotinic acetylcholine receptor *see* nAChR  
 nifedipine, 243  
 nitrendipine, 243, 244  
 nitric oxide, 221–2  
 NMDA receptor channels, 86  
 calcium influx through, 221  
 modulation by nitric oxide, 222  
 potentiation by glycine, 219, 249  
*N*-methyl-D-aspartate (NMDA), 248  
 noise, membrane, 46, 54  
 noise analysis *see* fluctuation analysis  
 noxiustoxin, 234, 235tab.  
 nucleotides, in DNA and RNA, 60–1  
  
 Ohm's law, 12, 29  
 okadaic acid, 217  
 olfactory transduction, 99  
 oocytes, *Xenopus*, expression in, 79–80  
 open channel block, 230, 241  
 open times, distribution of, 55–7, 163–6  
 openers of potassium channels, 234  
 organic cations, use in permeability studies, 144, 145fig., 145tab.  
  
 outside-out patch configuration, 48  
 oxytocin, 102  
  
 P region, 90, 237; *see also* H5 segment and SS1–SS2 section  
 P<sub>2N</sub> ATP receptor channel, 89  
 P/4 method for gating current, 180  
 P<sub>400</sub> protein, 105  
 PAM, 252  
 papers on channels, 263  
 parallel-activation models, 197–9  
 paramyotonia congenita (PC), 193, 252–3  
 partition coefficient, 123  
 patch clamp technique, 6fig., 46–52  
 discovery of, 5  
 pentameric structure  
 of nAChR, 69, 77  
 of related neurotransmitter-gated channels, 85  
 peptabols, 118  
 perforated patch, 49  
 periodic table, 13  
 permeability  
 binding site models of, 134–44  
 complex theories of, 122  
 defined, 121  
 independent electrodiffusion model, 122–9  
 permeability coefficient, *P*, 123  
 permeability sequence for different ions  
 CFTR channel, 109  
 pertussis toxin, 217  
 pH *see* hydrogen ions  
 pharmacology of channels, 225–49  
 phencyclidine, 248  
 phenylalkylamines, 243  
 phospholemmann, 114  
 phospholipase C, 105  
 phosphorylation, modulation by, 210–14  
 phosphorylation site, 72  
 in nAChR, 75  
 in voltage-gated sodium channel, 92  
 photosynthetic reaction centre, 72  
 picrotoxin, 246  
 pinacidil, 234  
 plasma membrane 1, 2fig.  
  
 point-amplitude histogram, 53, 54fig.  
 polyamines, 203, 249  
 polymerase chain reaction (PCR), 67  
 pore, channel, dimensions of, 4  
 porins, 73, 114–15, 148  
 potassium channels, ATP-sensitive  
 in  $\beta$  cell, 3  
 blocking agents of, 234  
 conductance of, 129  
 gating of, 205–6  
 kinetics of block, 228–9  
 reversal potential of, 125, 126fig.  
 sulphonylurea receptor and, 109  
 potassium channels, calcium activated  
 gating in, 201–2  
 as multi-ion pore, 141  
 phosphorylation of, 217  
 streaming potential in, 151  
 structure of, 97–8  
 potassium channels, inward rectifier  
 as multi-ion pores, 142  
 gating in, 202–5  
 nomenclature of, 102tab.  
 phosphorylation of, 217  
 questions about, 264–5  
 structure and diversity of, 100–2  
 potassium channels, sarcoplasmic reticulum  
 selectivity of, 127  
 streaming potential in, 151  
 potassium channels, voltage-gated  
 blocking agents of, 229–32, 234–6, 237fig.  
 dysfunctional mutants of, 255–6  
 gating of, 184, 187, 195, 197–8  
 H5 segment of, 152–4  
 kinetics of block, 228  
 long pore effect in, 131–2  
 molecular basis of selectivity in, 152–4  
 as multi-ion pores, 140–2  
 nomenclature of, 96tab.  
 parallel-activation model of, 197–8  
 pore lining of, 152  
 pore size, 146  
 selectivity of, 127tab., 146  
 structure and diversity of, 94–8  
 $\beta$ -subunits of, 192, 193fig.

- potassium-aggravated myotonia (PAM), 252–3, 254fig.
- potential difference, 10tab., 11
- primary structure, defined, 77
- probes, for DNA library, 67
- procaine, 240
- prolactin fusion protein, 76
- pronase, removal of inactivation by, 189
- protein kinase, 211
- protein kinase A, 206–7, 211–14, 216
- protein kinase C, 211, 212
- protein phosphatase, 211
- proteins, sequence determination of, 59–68
- putative, meaning of, 74
- pyrethrins, 240
- Q/R site, 88, 248
- quaternary ammonium ions, block by, 229–33
- quaternary structure of nAChR, 77–9
- quinoxalinediones, 248
- quisqualic acid, 86, 247
- R* (gas constant), 11tab., 24
- RACTK1, 102
- rate constant, 163  
 in nAChR, 172
- rate theory models, 134–7, 181, 264
- recombinant DNA technology, 64–8
- reconstitution, 44
- rectification  
 defined, 12  
 intrinsic, 203
- red tides, 237, 240
- resistance, 12
- resting potential, 34, 203
- restriction enzymes, 64–5
- reversal potential, 29, 125
- RNA, structure of, 61
- RNA editing, 88
- rod outer segment channels, 98
- ROMK channels, 100, 102tab., 203
- ryanodine, 103
- ryanodine receptor (RyR), 103–4, 219, 261–2
- S4 segment, 90  
 of cyclic-nucleotide-gated channels, 156, 201  
 role in gating, 185–8, 197
- sarcoplasmic reticulum, 103, 261
- saturation of conductance, 130
- saxitoxin, 237, 238
- scorpion toxins, 92, 234, 235tab., 238tab., 240
- screening, of DNA library, 66
- sea anemone toxins, 240
- second messengers, 214–18
- secondary structure, defined, 77
- selectivity, 2, 7fig., 121  
 GHK equations used to describe, 124–9  
 molecular basis of, 152–60
- selectivity filter, size of, 144–8, 157
- serotonin *see* 5-HT
- seven-transmembrane segment receptors, 215  
*Shab*, *Shaw* and *Shal*, 95, 96tab.
- Shaker* potassium channels,  
 gene encoding, 95  
 identification of, 67, 95  
 sister genes, 95
- shellfish poisoning, 237, 240
- sialic acid, 222
- signal sequence, 75
- single channel conductance ( $\gamma$ ), 29–31
- single channel current (*i*), 28–31
- single-strand conformational polymorphism (SSCP), 253
- SK channels, 98
- sliding helix model of S4 movement, 186, 187fig.
- slo* gene, 98, 201
- slope conductance, 30
- sodium channels, amiloride-sensitive, 102–3
- sodium channels, voltage-gated  
 auxiliary subunits in, 93, 193  
 binding site model of, 138–9  
 block by hydrogen ions, 137–9  
 blocking agents of, 236–42  
 calcium-permeable mutants of, 155  
 dysfunctional mutants of, 251–3, 254–5fig.  
 gating of, 179–80, 183–9, 195, 197
- modulation of, 212–13, 239–40
- molecular basis of selectivity in, 154–6.
- neurotoxin binding sites, 236, 238tab.
- phosphorylation of, 92fig., 212–13
- pore size, 144–6
- selectivity of, 126, 127tab., 144–6
- structure of, 91–93
- somatostatin, 217
- spermine, 203–4, 249
- spider toxins, 93, 244, 248
- splicing, alternative, 64  
 of glutamate receptors, 87–8  
 of *Shaker* potassium channels, 95
- splicing, of RNA, 64
- SS1–SS2 section, 90
- SSCP, 253
- startle disease, 260
- states, kinetic, 162
- stochastic nature of channel gating, 5, 162
- streaming potentials, 149–52
- stretch-activated channels, 207–9
- strychnine, 247
- subconductance levels, 55, 174, 203, 210
- subunits, 59  
 auxiliary, 93, 192–3  
 of GABA and glycine receptors, 84–5  
 of glutamate receptors, 86–7  
 of nAChR, 69, 77, 81–4  
 role in inactivation, 192–3  
 of voltage-gated channels, 90, 93, 192–3
- succinylcholine, 245, 261
- sulphonylurea drugs, 234
- sulphonylurea receptor, 109
- synthetic peptides, channel-forming, 118–19
- techniques, value of, 264
- tertiary structure, defined, 77
- tetraethylammonium (TEA), 226, 229
- tetrameric structure  
 of ryanodine receptor, 103  
 of voltage-gated channels, 90fig., 92, 95

- of voltage-gated potassium channels, 95
- tetrodotoxin  
 block by, 237, 238  
 discovery of, 4  
 uses, 91, 225–6, 238
- Thomsen's disease *see* myotonia congenita
- toxins  
 bacterial, 118  
 biological functions of, 225
- transfection, 81
- transition rate constant, 163
- transition time, 167
- transmembrane segments, 72  
 channels with two, 99–103  
 of CLC channel, 107  
 of connexins, 111  
 identification of, 75  
 of nAChR, 74–7  
 of ryanodine receptor, 103  
 of voltage-gated channels, 90
- transcription, 61
- translation, 62
- triethylnonylammonium *see* C<sub>9</sub>
- tunnel, in potassium channel pore, 231
- two-state channel  
 block in, 226–9  
 kinetics of, 162–4, 168–70, 181
- uK<sub>ATP</sub>-1 channel, 101, 102tab.  
 use-dependent block, 241
- van der Waals forces, 16, 17tab.
- vasopressin, 102
- VDAC (voltage-dependent anion channel), 115
- vector, 64
- verapamil, 243
- veratridine, 240
- vestibule, of channel pore, 152, 236, 237fig., 241; *see also* antechamber
- visual transduction, 99
- voltage clamp technique, 35–9
- voltage sensor, 7fig., 90–1; *see also* S4 segment
- voltage-gated channels  
 gating in, 178–99  
 pore size of, 144–8  
 selectivity of, 126–7  
 structure of, 89–99  
*see also under* calcium channels, potassium channels, and sodium channels
- wasp toxins, 248
- water  
 in channel pore, 148–9, 188  
 in hydrated ions, 20, 136  
 movement in gating, 188, 197  
 structure of, 15, 16, 21, 148
- water channels, 113
- WCH-CD, 113
- whole-cell patch recording, 49
- $\zeta\delta$  *see* electrical distance